oral glp 1 tirzepatide Dissolving Tablets - Needle-Free GLP-1/GIP Weight Loss Buy Oral Tirzepatide Online |

A novel oral formulation of the GLP-1 receptor agonist semaglutide (Rybelsus) was recently approved for the treatment of T2DM

Avoid products with artificial flavors, seed oils, or unnecessary sugars

note that daily dosing is only for the activation phase of the GLOW protocol (weeks 1-4) , decreasing to 5x per week for the remodeling phase (weeks 5-8), and further reduced to 2-3x per week during maintenance (weeks 9-12)

To meet the diagnostic criteria for kEDS, a person must meet: Major criterion 1 AND major criterion 2 AND major criterion 3 OR Major criterion 1 AND major criterion 2 AND three minor criteria (general or gene-specific) Major Criteria Congenital muscle hypotonia Congenital or early onset kyphoscoliosis (progressive or non-progressive) Generalized joint hypermobility with dislocations/subluxations (shoulders, hips, and knees in particular) Minor Criteria Skin hyperextensibility Easily bruisable skin Rupture/aneurysm of a medium-sized artery Osteopenia/osteoporosis Blue sclerae Hernia (umbilical or inguinal) Pectus deformity Marfanoid habitus Talipes equinovarus Refractive errors (myopia, hypermetropia) Gene-Specific Minor Criteria PLOD1 Skin fragility (easy bruising, friable skin, poor wound healing, widened atrophic scarring) Scleral and ocular fragility/rupture Microcornea Facial dysmorphology FKBP14 Congenital hearing impairment (sensorineural, conductive, or mixed) Follicular hyperkeratosis Muscle atrophy Bladder diverticula Musculocontractural EDS (mcEDS) If a person meets the diagnostic criteria for mcEDS, genetic testing should be done to confirm the diagnosis

For some the benefits are outweighed by the potential side effects: elevated hematocrit levels, estrogen imbalances, and perhaps most alarmingly, shrinking testicles and decreased fertility markers

And so, you know, if we just keep on going the way were going